Biomarkers Evaluated for Subconcussive Head Trauma
By LabMedica International staff writers Posted on 12 Jun 2018 |

Image: The Simoa single molecule array HD-1 analyzer (Photo courtesy of Quanterix).
Repetitive subconcussive head trauma is a consequence of participation in contact sports and may be linked to neurodegenerative diseases. The degree of neurological injury caused by subconcussive head trauma is not easily detectible, and this injury does not induce readily identifiable clinical signs or symptoms.
The accumulation of subconcussive head impacts over the course of a football season has been linked to neurophysiological and neuropsychological changes in athletes, and the accumulation of subconcussive head impacts over a long career has been suggested as a cause of severe neurodegenerative diseases such as Alzheimer's disease and chronic traumatic encephalopathy (CTE).
Scientists at the Texas Christian University (Fort Worth, TX, USA) and their colleagues obtained blood samples from thirty-five National Collegiate Athletic Association (NCAA) football players on seven different days, beginning before fall camp commenced and ending three weeks after the competitive football season had finished. The investigators wanted to examine fluctuations in plasma concentrations of tau and serum concentrations of neurofilament light polypeptide (NF-L) over the course of the entire football season, during which the number and magnitude of head impacts varied.
After blood collection, subsequent centrifugation is done at 2000g for 20 minutes at 4 °C within 30 minutes after collection. Following centrifugation, samples were transferred to prelabeled polypropylene vials and stored at −80 °C until biomarker quantification. Plasma concentrations of tau (Simoa Tau 2.0 Kit) and serum concentrations of NF-L (Simoa Beta Kit) were measured using digital array technology on a Simoa Single Molecule Array HD-1 Analyzer, software version 1.5. The same lot of kits was used to assay both tau and NF-L. Athletes were grouped based on their starter status, because athletes identified as starters are known to sustain a greater number of impacts. Between-group differences and time-course differences were assessed.
The scientists found that nonstarters, plasma concentrations of tau decreased over the course of the season, with lower values observed in starters; this resulted in a lower area under the curve (AUC) (starters: 416.78 ± 129.17 pg/mL/day; nonstarters: 520.84 ± 163.19 pg/mL/day). Plasma concentrations of tau could not be used to discern between starters and nonstarters. In contrast, serum concentrations of NF-L increased throughout the season as head impacts accumulated, specifically in those athletes categorized as starters. The higher serum concentrations of NF-L observed in starters resulted in a larger AUC (starters: 1,605.03 ± 655.09 pg/mL/day; nonstarters: 1,067.29 ± 272.33 pg/mL/day).
The authors concluded that the different patterns observed in serum NF-L and plasma tau concentrations provide preliminary evidence for the use of blood biomarkers to detect the neurological injury associated with repetitive subconcussive head trauma.
Jonathan M. Oliver, PhD, an Assistant Professor and the lead author of the study, said, “Given recent findings indicating a potential link between repetitive subconcussive impacts and the development of CTE, efforts to determine the effect of subconcussive impacts throughout an athlete's career may prove useful, especially if those efforts are feasible and cost effective.” The study was published on May 29, 2018, in the Journal of Neurosurgery.
Related Links:
Texas Christian University
The accumulation of subconcussive head impacts over the course of a football season has been linked to neurophysiological and neuropsychological changes in athletes, and the accumulation of subconcussive head impacts over a long career has been suggested as a cause of severe neurodegenerative diseases such as Alzheimer's disease and chronic traumatic encephalopathy (CTE).
Scientists at the Texas Christian University (Fort Worth, TX, USA) and their colleagues obtained blood samples from thirty-five National Collegiate Athletic Association (NCAA) football players on seven different days, beginning before fall camp commenced and ending three weeks after the competitive football season had finished. The investigators wanted to examine fluctuations in plasma concentrations of tau and serum concentrations of neurofilament light polypeptide (NF-L) over the course of the entire football season, during which the number and magnitude of head impacts varied.
After blood collection, subsequent centrifugation is done at 2000g for 20 minutes at 4 °C within 30 minutes after collection. Following centrifugation, samples were transferred to prelabeled polypropylene vials and stored at −80 °C until biomarker quantification. Plasma concentrations of tau (Simoa Tau 2.0 Kit) and serum concentrations of NF-L (Simoa Beta Kit) were measured using digital array technology on a Simoa Single Molecule Array HD-1 Analyzer, software version 1.5. The same lot of kits was used to assay both tau and NF-L. Athletes were grouped based on their starter status, because athletes identified as starters are known to sustain a greater number of impacts. Between-group differences and time-course differences were assessed.
The scientists found that nonstarters, plasma concentrations of tau decreased over the course of the season, with lower values observed in starters; this resulted in a lower area under the curve (AUC) (starters: 416.78 ± 129.17 pg/mL/day; nonstarters: 520.84 ± 163.19 pg/mL/day). Plasma concentrations of tau could not be used to discern between starters and nonstarters. In contrast, serum concentrations of NF-L increased throughout the season as head impacts accumulated, specifically in those athletes categorized as starters. The higher serum concentrations of NF-L observed in starters resulted in a larger AUC (starters: 1,605.03 ± 655.09 pg/mL/day; nonstarters: 1,067.29 ± 272.33 pg/mL/day).
The authors concluded that the different patterns observed in serum NF-L and plasma tau concentrations provide preliminary evidence for the use of blood biomarkers to detect the neurological injury associated with repetitive subconcussive head trauma.
Jonathan M. Oliver, PhD, an Assistant Professor and the lead author of the study, said, “Given recent findings indicating a potential link between repetitive subconcussive impacts and the development of CTE, efforts to determine the effect of subconcussive impacts throughout an athlete's career may prove useful, especially if those efforts are feasible and cost effective.” The study was published on May 29, 2018, in the Journal of Neurosurgery.
Related Links:
Texas Christian University
Latest Clinical Chem. News
- AI-Powered Blood Test Accurately Detects Ovarian Cancer
- Automated Decentralized cfDNA NGS Assay Identifies Alterations in Advanced Solid Tumors
- Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication
- First Comprehensive Syphilis Test to Definitively Diagnose Active Infection In 10 Minutes
- Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse
- ‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection
- Low-Cost Portable Screening Test to Transform Kidney Disease Detection
- New Method Uses Pulsed Infrared Light to Find Cancer's 'Fingerprints' In Blood Plasma
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
Channels
Molecular Diagnostics
view channel
POC Diagnostic Platform Combines Immunoassay and Molecular Testing
An innovative diagnostic platform offers superior sensitivity across all sample types, including blood, compared to existing rapid tests, while maintaining a low-cost, user-friendly design.... Read more
Single Blood Test Could Detect Different Types of Cancer at Early Stages
Currently, reliable screening for only a few types of cancer is available, such as those affecting the breast, bowel, cervix (neck of the womb), and lung for individuals at high risk. While these screenings... Read moreHematology
view channel
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read more
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
New Blood Test Detects Up to Five Infectious Diseases at POC
Researchers have developed a prototype flow-through assay capable of detecting up to five different infections, with results that can be quickly analyzed and transmitted via a specialized smartphone app.... Read more
Molecular Stool Test Shows Potential for Diagnosing TB in Adults with HIV
Tuberculosis (TB), caused by the bacterium Mycobacterium tuberculosis, led to 1.25 million deaths in 2023, with 13% of those occurring in people living with HIV. The current primary diagnostic method for... Read morePathology
view channel
Groundbreaking Chest Pain Triage Algorithm to Transform Cardiac Care
Cardiovascular disease is responsible for a third of all deaths worldwide, and chest pain is the second most common reason for emergency department (ED) visits. With EDs often being some of the busiest... Read more
AI-Based Liquid Biopsy Approach to Revolutionize Brain Cancer Detection
Detecting brain cancers remains extremely challenging, with many patients only receiving a diagnosis at later stages after symptoms like headaches, seizures, or cognitive issues appear. Late-stage diagnoses... Read moreTechnology
view channel
Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer
Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses
Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples
As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read moreIndustry
view channel
Qiagen Acquires NGS Analysis Software Company Genoox
QIAGEN (Venlo, the Netherlands) has signed a definitive agreement to acquire Genoox (Tel Aviv, Israel), a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and... Read more
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more